U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size is USD 372.05 Million in 2026

U.S. Knee Osteoarthritis (OA) Injectable Treatments Market (By Product Type: Viscosupplements, Stem Cell Therapy Injections, Botulinum Toxin Injections, Combination Injections, Other Biologic Injections; By Mechanism of Action: Lubrication, Anti-inflammatory, and Regenerative; By Disease Severity: Mild Knee OA, Moderate Knee OA, and Severe Knee OA; By Age Group: 40–60 Years and Above 60 Years; By Duration/Dosing Frequency: Weekly over 3–5 Weeks, Multiple Dose Regimen, Single-Dose Therapy, and Monthly; By End Use: Orthopedic Clinics, Hospitals, Ambulatory Surgical Centers (ASCs), Sports Medicine Clinics, and Research Institutes / Regenerative Medicine Centers) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 672 | Published : 12 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 35 Mn

Forecast Year,

USD 644.76 Mn

CAGR, 2026 - 2035

6.3%

Report Coverage

U.S.

Download Databook

The U.S. knee osteoarthritis (OA) injectable treatments market size was estimated at USD 350 million in 2025 and is projected to be worth around USD 644.76 million by 2035, growing at a CAGR of 644.76% from 2026 to 2035. The rising prevalence of osteoarthritis and demand for advanced treatment are boosting the market.

U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 350 Billion
Market Size in 2026	USD 372.05 Billion
Market Size by 2035	USD 644.76 Billion
CAGR 2026 to 2035	6.3%
Base Year	2025
Forecast Period	2026 to 2035

The U.S. knee osteoarthritis (OA) injectable treatments market is rapidly expanding. Aging is a complex process that leads to the accumulation of molecular, cellular, and organ damage, making individuals more susceptible to osteoarthritis and related health conditions.

Increased research and development activities for injectable drug development are driving market growth. The management of osteoarthritis is challenging due to the dense, avascular tissue structure. The introduction of intra-articular administration of drugs for osteoarthritis has accelerated the development of targeted drug delivery systems.

Segments	Shares (%)
Viscosupplements	50%
Stem Cell Therapy Injections	25%
Botulinum Toxin Injections	10%
Combination Injections	10%
Other Biologic Injections	5%

Viscosupplements - Injections that provide lubrication to the knee joint, accounting for 50.00% share. The viscosupplements segment dominated due to their widespread use, patient compliance and efficacy in managing knee OA symptoms.
Stem cell therapy injections - Injections using stem cells for regenerative purposes, the stem cell therapy injection segment held 25.00% share, and is gaining momentum due to growing interest in regenerative medicine and the potential for long-term relief.

Segments	Shares (%)
Lubrication	60%
Anti-inflammatory	25%
Regenerative	15%

Lubrication - Injections designed to enhance joint lubrication, the lubrication segment held a dominating 60.00% share. This dominance is due to their common use in alleviating pain and enhancing joint function in knee OA patients.
Anti-inflammatory - Injections that reduce inflammation, the anti-inflammatory segment held 25.00% share, driven by emerging biological, anti-inflammatory therapies and increasing demand for advanced, sustained-release anti-inflammatory injections.

Segments	Shares (%)
Moderate Knee OA	50%
Severe Knee OA	20%
Mild Knee OA	30%

Moderate knee OA - Knee OA with moderate severity held 50.00% share. This segment dominated as it represents the largest patient group requiring intervention with injectable treatments, and the U.S. leads to a higher incidence of moderate knee OA.
Mild knee OA - the mild knee OA segment held 30% share, driven by increasing geriatric population susceptible to OA, along with increasing obesity rates, has boosted the prevalence of early-stage knee OA.

Segments	Shares (%)
40–60 Years	45%
> 60 years	55%

40-60 years - The most common age group for knee OA treatments, the 40-60 years segment held the dominant share of 45.00% share, due to the higher prevalence of knee OA in this demographic and active individuals seek early interventions.
>60 years - Older adults aged 60 and above, held 55.00% share, have a significant share due to the growing elderly population in the U.S and higher incidence of knee OA in elderly populations.

Segments	Shares (%)
Weekly over 3–5 weeks	15%
Multiple dose regimen	50%
Single-Dose Therapy	25%
Monthly	10%

Multiple Dose Regimen - Ongoing injections to give continuous symptom relief. The multiple dose regimen dominated with 50% share due to the demand for prolonged symptom management in moderate to severe cases of knee OA.
Single-Dose Therapy - A one-time injection gives relief from knee OA symptoms. The single-dose therapy segment held 25% share mainly due to convenience, reduced clinic visits, and superior clinical outcomes.

Segments	Shares (%)
Orthopedic clinics	25%
Hospitals	40%
Ambulatory Surgical Centers (ASCs)	15%
Sports Medicine Clinics	11%
Research Institutes / Regenerative Medicine Centers	9%

Hospitals - hospitals are medical facilities offering comprehensive care for knee OA patients. The hospitals segment dominated with 40% share due to the important role of hospitals in offering advanced treatments and in the management of complex cases.
Orthopedic clinics - Specialized clinics offering treatments for musculoskeletal conditions. The orthopedic clinics segment held 25% share due to growing demand for outpatient, non-surgical, and same-day joint pain treatments.

Top Companies in the U.S. Knee Osteoarthritis (OA) Injectable Treatments Marketet

Alcon, Inc.
Allergan plc
Anika Therapeutics, Inc.
Arthrex, Inc.
Bioventus, Inc.
Ferring Pharmaceuticals Inc.
Fidia Farmaceutici S.p.A.
Flexion Therapeutics, Inc.
Galderma S.A.
Hyaltech Ltd.
Landec Corporation (LifeCore Biomedical, Inc.)
Meiji Seika Pharma Ltd.
Merz Pharmaceuticals GmbH (Merz Aesthetics, Inc.)
OrthogenRx, Inc.
Roche Holding AG (F. Hoffmann-La Roche AG)
Royal Biologics
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zimmer Biomet

Segments Covered in the Report

By Product Type

Viscosupplements
Stem Cell Therapy Injections
Botulinum Toxin Injections
Combination Injections
Other Biologic Injections

By Mechanism of Action

Lubrication
Anti-inflammatory
Regenerative

By Disease Severity

Moderate Knee OA
Severe Knee OA
Mild Knee OA

By Age Group

40–60 Years
60 years

By Duration/Dosing Frequency

Weekly over 3–5 weeks
Multiple dose regimen
Single-Dose Therapy
Monthly

By End Use

Orthopedic clinics
Hospitals
Ambulatory Surgical Centers (ASCs)
Sports Medicine Clinics
Research Institutes / Regenerative Medicine Centers

List of Tables & Figures

List of Tables

Table 1: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Product Type, 2025-2035 (USD Million)
Table 2: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mechanism of Action, 2025-2035 (USD Million)
Table 3: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Disease Severity, 2025-2035 (USD Million)
Table 4: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Age Group, 2025-2035 (USD Million)
Table 5: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Duration/Dosing Frequency, 2025-2035 (USD Million)
Table 6: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by End Use, 2025-2035 (USD Million)
Table 7: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Viscosupplements, 2025-2035 (USD Million)
Table 8: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Stem Cell Therapy Injections, 2025-2035 (USD Million)
Table 9: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Botulinum Toxin Injections, 2025-2035 (USD Million)
Table 10: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Combination Injections, 2025-2035 (USD Million)
Table 11: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Other Biologic Injections, 2025-2035 (USD Million)
Table 12: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Lubrication, 2025-2035 (USD Million)
Table 13: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Anti-inflammatory, 2025-2035 (USD Million)
Table 14: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Regenerative, 2025-2035 (USD Million)
Table 15: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Moderate Knee OA, 2025-2035 (USD Million)
Table 16: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Severe Knee OA, 2025-2035 (USD Million)
Table 17: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mild Knee OA, 2025-2035 (USD Million)
Table 18: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 40-60 Years, 2025-2035 (USD Million)
Table 19: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 60 Years and Above, 2025-2035 (USD Million)
Table 20: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Weekly over 3-5 Weeks, 2025-2035 (USD Million)
Table 21: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Multiple Dose Regimen, 2025-2035 (USD Million)
Table 22: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Single-Dose Therapy, 2025-2035 (USD Million)
Table 23: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Monthly, 2025-2035 (USD Million)
Table 24: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Orthopedic Clinics, 2025-2035 (USD Million)
Table 25: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Hospitals, 2025-2035 (USD Million)
Table 26: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Ambulatory Surgical Centers (ASCs), 2025-2035 (USD Million)
Table 27: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Sports Medicine Clinics, 2025-2035 (USD Million)
Table 28: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Research Institutes / Regenerative Medicine Centers, 2025-2035 (USD Million)

List of Figures

Figure 1: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Product Type, 2025 (%)
Figure 2: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Mechanism of Action, 2025 (%)
Figure 3: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Disease Severity, 2025 (%)
Figure 4: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Age Group, 2025 (%)
Figure 5: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Duration/Dosing Frequency, 2025 (%)
Figure 6: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Share, by End Use, 2025 (%)
Figure 7: U.S. Knee Osteoarthritis (OA) Injectable Treatments Market Forecast, 2025-2035 (USD Million)
Figure 8: Viscosupplements Segment Market Forecast, 2025-2035 (USD Million)
Figure 9: Stem Cell Therapy Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 10: Botulinum Toxin Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 11: Combination Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 12: Other Biologic Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 13: Lubrication Segment Market Forecast, 2025-2035 (USD Million)
Figure 14: Anti-inflammatory Segment Market Forecast, 2025-2035 (USD Million)
Figure 15: Regenerative Segment Market Forecast, 2025-2035 (USD Million)
Figure 16: Moderate Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 17: Severe Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 18: Mild Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 19: 40-60 Years Segment Market Forecast, 2025-2035 (USD Million)
Figure 20: 60 Years and Above Segment Market Forecast, 2025-2035 (USD Million)
Figure 21: Weekly over 3-5 Weeks Segment Market Forecast, 2025-2035 (USD Million)
Figure 22: Multiple Dose Regimen Segment Market Forecast, 2025-2035 (USD Million)
Figure 23: Single-Dose Therapy Segment Market Forecast, 2025-2035 (USD Million)
Figure 24: Monthly Segment Market Forecast, 2025-2035 (USD Million)
Figure 25: Orthopedic Clinics Segment Market Forecast, 2025-2035 (USD Million)
Figure 26: Hospitals Segment Market Forecast, 2025-2035 (USD Million)
Figure 27: Ambulatory Surgical Centers (ASCs) Segment Market Forecast, 2025-2035 (USD Million)
Figure 28: Sports Medicine Clinics Segment Market Forecast, 2025-2035 (USD Million)
Figure 29: Research Institutes / Regenerative Medicine Centers Segment Market Forecast, 2025-2035 (USD Million)

Research Methodology

Related Databooks

March 2026